Company intelligence / Profile preview
Neuro Vigor Therapeutics
Indiana, United Statesnvtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Neuro Vigor’s lead candidate NVG291 has completed Phase 1 trials. The company is advancing its RAS-inhibiting small molecules targeting neuropathic pain in spinal cord injury. Preclinical data support expansion into other neuropathic pain types and neurodegenerative diseases where RAS contributes to pathology.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule drugs targeting reactive aldehyde species (RAS)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Western Australia collaboration focusing on novel RAS-trapping compounds with exclusive licensing options[10]Participation in NIH/NINDS PSPP program for non-opioid analgesics screening[10]Indiana State Department of Health grant support for SCI neuropathic pain research[10]
Beyond the preview
Go deeper on Neuro Vigor Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuro Vigor Therapeutics.